FDA Approval Process for Novel Antipsychotic Development

This document is a case study detailing the partnership between a biopharmaceutical company and Premier Research in the development of a novel combination antipsychotic for a psychiatric disorder. It outlines the complexities involved in conducting clinical trials for psychiatric conditions, which are influenced by various genetic, biological, social, and environmental factors. The case study describes how Premier Research was engaged as the sole contract research organization (CRO) to manage proof-of-concept studies from Phase 2 through to FDA approval. It highlights the collaborative efforts between the sponsor and Premier Research, including the establishment of a joint operations committee to enhance planning and risk management. The document also presents the outcomes of six Phase 3 studies, which enrolled 1,655 patients and resulted in FDA approval for two psychiatric indications. The partnership is characterized by trust and proactive engagement, showcasing the importance of innovative processes in ensuring data quality and study success.